1. History and mission
Regenerative medicine is one of the most dynamic areas of research in the biomedical research and is of central importance for the development of translational medicine. The aim of regenerative medicine is the restoration of dysfunctional cells, tissues or organs by stimulating the body's own repair or regeneration processes or by biological replacement of tissue engineered living cells, tissues or biomaterials in the laboratory.
In 2015, Wyss Zurich, biotechnet and the NTN SwissBiotech founded a novel platform namend "Regenerative Medicine". In order to sharpen its activities and competencies the name of the platform has been redefined from "Regenerative Medicine" towards "Translational and Clinical Bio-Manufacturing (TCBM)" in 2017. In November 2017, the network "Stem Cell Research in Regenerative Medicine (SCRM) joined the NTN biotechnet as full member and is heading together with Wyss Zurich the platform TCBM. The mission of the TCBM platform is to bundle the existing expertise of regenerative medicine activities in Switzerland with a focus on the translation from the pre-clinical phase towards therapeutic biomedical applications. Networking activities facilitated through the platform "Translational and Clinical Bio-Manufacturing" will lead to novel research co-operations between academic patrners. Together, we endeavor to innovate regenerative medicine development on the academic level.
2. Platform members
The platform is led by Dr. Steffen M. Zeisberger and Prof. Eliane Müller and has multiple (inter-)national industrial and academic collaboration partners (please see and explore links under chapter 4).
2.1 How to become a TCBM-platform partner
To become a TCBM-platform partner, please contact Dr. Steffen M. Zeisberger or Prof. Eliane Müller for details. The partnership fees are:
Academy CHF 500.- p.a.
Spin-off / industry CHF 2'000.- p.a.
3. Events and News
Please visit events and news on this homepage
Stem Cell Research in Regenerative Medicine